2020•Unpublished venueRequires access

Review for "Inhibition of fatty acid synthase with FT ‐4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with NAFLD non‐alcoholic fatty liver disease: results from two early phase randomized trials"

Author information unavailable

Open publisher page 0 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Lipogenesis, Steatosis, Fatty acid synthase, Fatty liver, Internal medicine, ATP synthase, Endocrinology, Chemistry

Back to paper search Browse research topics Original source

Review for "Inhibition of fatty acid synthase with FT ‐4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with NAFLD non‐alcoholic fatty liver disease: results from two early phase randomized trials" — Research Paper | ScholarLens